Active, not recruitingInterventional · Phase 2NCT02365597 ↗A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGFR Genomic Alterations
RecruitingInterventional · Phase 2NCT02523014 ↗Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway MutationsRajiv S. MaggePIInterventionDrug: Vismodegib · Drug: FAK Inhibitor GSK2256098 · Drug: Capivasertib · Drug: AbemaciclibDatesSep 2015 – Jun 2028 (est.)SponsorAlliance for Clinical Trials in OncologyIntracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
RecruitingInterventional · Phase 2NCT02974647 ↗Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaJia RuanPIInterventionDrug: RuxolitinibDatesNov 2016 – Nov 2027 (est.)SponsorMemorial Sloan Kettering Cancer CenterLymphoma
Active, not recruitingInterventional · Phase 2NCT03092856 ↗Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell CarcinomaAna M. MolinaPIInterventionBiological: Anti-OX40 Antibody PF-04518600 · Drug: Axitinib · Other: Laboratory Biomarker Analysis · Other: PlaceboDatesJul 2017 – Dec 2026 (est.)SponsorUSC Keck School of Medicine Norris Cancer CenterClear Cell Renal Cell CarcinomaMetastatic Renal Cell CancerRecurrent Renal Cell Carcinoma+1 more
Active, not recruitingInterventional · Phase 2NCT03371719 ↗A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)Hani Lamie AshamallaPIInterventionDrug: Apalutamide · Radiation: External Beam Radiation Therapy · Other: Placebo AdministrationDatesJun 2018 – Mar 2025· Results postedSponsorNRG OncologyRecurrent Prostate CarcinomaStage III Prostate Adenocarcinoma AJCC v7Stage IV Prostate Adenocarcinoma AJCC v7
Active, not recruitingInterventional · Phase 2NCT03375307 ↗A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair DefectsCora SternbergPIInterventionProcedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Bone Marrow Biopsy · Procedure: Bone Scan · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Drug: Olaparib · Procedure: Positron Emission TomographyDatesNov 2020 – Dec 2026 (est.)SponsorNational Cancer InstituteAdvanced Bladder CarcinomaAdvanced Genitourinary System CarcinomaMetastatic Bladder Carcinoma+3 more
Active, not recruitingInterventional · Phase 2NCT03407144 ↗An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)Lisa Giulino RothPIInterventionBiological: pembrolizumab · Drug: doxorubicin · Drug: vinblastine · Drug: dacarbazine · Drug: cyclophosphamide · Drug: vincristine · Drug: prednisone/prednisolone · Drug: bleomycin · Drug: etoposide · Radiation: Radiotherapy (RT)DatesApr 2018 – Feb 2027 (est.)SponsorChildren's Oncology GroupHodgkin Lymphoma
Active, not recruitingInterventional · Phase 2NCT03485209 ↗Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid TumorsElizabeta Cristina PopaPIInterventionDrug: tisotumab vedotin · Drug: pembrolizumab · Drug: carboplatin · Drug: cisplatinDatesJun 2018 – Mar 2026SponsorSeattle Genetics, Inc.Colorectal NeoplasmsCarcinoma, Non-Small-Cell LungExocrine Pancreatic Cancer+1 more
Active, not recruitingInterventional · Phase 2NCT03505320 ↗A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination With Chemotherapy and/or Immunotherapy in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma Whose Are Claudin (CLDN) 18.2 PositiveManish A ShahPIInterventionDrug: zolbetuximab · Drug: oxaliplatin · Drug: leucovorin · Drug: fluorouracil · Drug: Pembrolizumab · Drug: folinic acid · Drug: nivolumab · Drug: DocetaxelDatesJun 2018 – Jun 2027 (est.)SponsorAstellas Pharma Inc.Pharmacokinetics of ZolbetuximabGastric CancerGastro-esophageal Junction (GEJ) Cancer+2 more
Active, not recruitingInterventional · Phase 2NCT03547973 ↗A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial CancerScott T. TagawaPIInterventionDrug: Sacituzumab Govitecan-hziy · Drug: Pembrolizumab · Drug: Cisplatin · Drug: Avelumab · Drug: Zimberelimab · Drug: Carboplatin · Drug: Gemcitabine · Drug: Domvanalimab · Drug: Enfortumab VedotinDatesAug 2018 – Apr 2030 (est.)SponsorImmunomedics, Inc.Metastatic Urothelial Cancer
Active, not recruitingInterventional · Phase 2NCT03600701 ↗A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung CancerAshish SaxenaPIInterventionDrug: Atezolizumab · Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Cobimetinib · Procedure: Computed Tomography · Procedure: Magnetic Resonance ImagingDatesNov 2018 – Jul 2025· Results postedSponsorNational Cancer InstituteMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell Carcinoma+1 more
Active, not recruitingInterventional · Phase 2NCT03604198 ↗An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing SyndromeGeorgiana Alina DobriPIInterventionDrug: relacorilantDatesMay 2018 – Dec 2026 (est.)SponsorCorcept Therapeutics IncorporatedCushing Syndrome
RecruitingInterventional · Phase 2NCT03606967 ↗Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast CancerMassimo CristofanilliPIInterventionProcedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Biological: Durvalumab · Drug: Gemcitabine Hydrochloride · Procedure: Magnetic Resonance Imaging · Drug: Nab-paclitaxel · Biological: Personalized Synthetic Long Peptide Vaccine · Drug: Poly ICLC · Biological: Sacituzumab Govitecan · Biological: TremelimumabDatesApr 2021 – Dec 2026 (est.)SponsorNational Cancer InstituteAnatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaMetastatic Triple-Negative Breast Carcinoma
Active, not recruitingInterventional · Phase 2NCT03712202 ↗A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)Jia RuanPIInterventionDrug: Bleomycin · Drug: Brentuximab Vedotin · Drug: Dacarbazine · Drug: Doxorubicin · Biological: Nivolumab · Other: Quality-of-Life Assessment · Drug: VinblastineDatesNov 2018 – Nov 2024· Results postedSponsorCity of Hope National Medical CenterAnn Arbor Stage I Hodgkin LymphomaAnn Arbor Stage I Mixed Cellularity Classic Hodgkin LymphomaAnn Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma+11 more
Active, not recruitingInterventional · Phase 2NCT03722407 ↗A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 ExpansionGail J RobozPIInterventionDrug: RuxolitinibDatesAug 2019 – Sep 2022· Results postedSponsorH. Lee Moffitt Cancer Center & Research InstituteChronic Myelomonocytic LeukemiaLeukemia
Active, not recruitingInterventional · Phase 2NCT03725761 ↗A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed TherapyScott T. TagawaPIInterventionDrug: Sacituzumab GovitecanDatesOct 2018 – Apr 2024· Results postedSponsorUniversity of WisconsinProstate Cancer
RecruitingInterventional · Phase 2NCT03739814 ↗A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory DiseaseEllen K. RitchiePIInterventionProcedure: Biospecimen Collection · Biological: Blinatumomab · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Biological: Inotuzumab Ozogamicin · Procedure: Lumbar Puncture · Drug: PonatinibDatesMay 2019 – Feb 2027 (est.)SponsorAlliance for Clinical Trials in OncologyB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
Active, not recruitingInterventional · Phase 2NCT03767348 ↗An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]Anna C PavlickPIInterventionBiological: RP1 · Biological: nivolumabDatesSep 2017 – Jun 2028 (est.)SponsorReplimune Inc.Non-Small Cell Lung Cancer (NSCLC)Microsatellite Instability-High (MSI-H)Non-melanoma Skin Cancer (NMSC)+1 more
RecruitingInterventional · Phase 2NCT03804944 ↗Converting HR+ Breast Cancer Into an Individualized VaccineSilvia Chiara FormentiPIInterventionRadiation: Focal Radiation therapy · Drug: Pembrolizumab (200mg IV for 30 minutes · Biological: CDX-301DatesMar 2020 – Dec 2026 (est.)SponsorWeill Medical College of Cornell UniversityBreast Cancer
Active, not recruitingInterventional · Phase 2NCT03817398 ↗Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)Alexander Ja-Ho ChouPIInterventionProcedure: Biospecimen Collection · Other: Drug Withdrawn · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Drug: Tyrosine Kinase InhibitorDatesNov 2019 – Sep 2026 (est.)SponsorChildren's Oncology GroupChronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive